Tezcat Biosciences, Inc.
New Haven, CT
- UEI
- E6EJYYD5BJ23
- CAGE
- 89QN3
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- Regal Home Warranty, 470 James St Suite 007, New Haven, CT 06513, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Tumor-targeted delivery of radio/chemotherapy in pancreatic cancer. - project summary tezcat biosciences is developing… | National Cancer Institute | $399,855 | |
| A novel monobody-drug conjugate to treat mutant kras pancreatic cancer. - project summary tezcat biosciences is… | National Cancer Institute | $3,155,212 | |
| A novel monobody-drug conjugate to treat mutant kras pancreatic cancer. - project summary: tezcat laboratories LLC is an… | National Cancer Institute | $419,972 | |
| A novel monobody-drug conjugate to treat mutant RAS multiple myeloma - tezcat is an early-stage, biopharmaceutical… | National Cancer Institute | $3,329,290 | |
| A novel monobody-drug conjugate to treat mutant RAS multiple myeloma | National Cancer Institute | $399,877 |
About Tezcat Biosciences, Inc.
Tezcat Biosciences, Inc. is an early-stage biotechnology company based in Austin, Texas, developing novel biologics with a unique mechanism of action to treat recalcitrant cancers such as mutant KRAS pancreatic cancer and mutant RAS multiple myeloma. The company is registered in SAM.gov as a Minority Owned Business, Hispanic American Owned, and For Profit Organization.
Through prime federal grant awards from the National Institutes of Health's National Cancer Institute, Tezcat Biosciences has developed protein-drug conjugates that utilize a macropinocytosis-selective monobody to carry an FDA-approved cytotoxic payload. The conjugates target mutant KRAS pancreatic cancer cells and mutant RAS multiple myeloma cells by exploiting their high levels of macropinocytosis, a nutrient scavenging process. Tezcat Biosciences has been awarded over $1.8 million in funding to evaluate the lead drug candidates' ability to control cancer growth in mouse models, pursue bioanalytical assay development, conduct non-GLP toxicology studies in rats, and prepare for a pre-IND meeting with the FDA. The company aims to establish initial efficacy and nontoxicity of the lead compounds, further develop them towards IND status, and ultimately conduct first-in-human clinical trials through strategic partnerships.
Quick answers
What is Tezcat Biosciences, Inc.'s UEI?
Tezcat Biosciences, Inc.'s Unique Entity ID (UEI) in SAM.gov is E6EJYYD5BJ23.
What is Tezcat Biosciences, Inc.'s CAGE code?
Tezcat Biosciences, Inc.'s CAGE code is 89QN3.
Where is Tezcat Biosciences, Inc. located?
Tezcat Biosciences, Inc.'s physical address in SAM.gov is Regal Home Warranty, 470 James St Suite 007, New Haven, CT 06513, USA.
Is Tezcat Biosciences, Inc. registered in SAM.gov?
Yes. Tezcat Biosciences, Inc.'s SAM.gov registration is active through March 5, 2027.
What is Tezcat Biosciences, Inc.'s most recent federal award?
Tezcat Biosciences, Inc.'s most recent federal grant award is Tumor-targeted delivery of radio/chemotherapy in pancreatic cancer. - project summary tezcat biosciences is developing… (R41CA306696), from National Cancer Institute, on August 18, 2026.
On GovTribe
See Tezcat Biosciences, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors